Matching articles for "oritavancin"
Issue 1631 · August 23, 2021 Free
In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)

The FDA has approved Kimyrsa (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused…

Med Lett Drugs Ther. 2021 Aug 23; 63(1631):e1-2
The FDA has approved Kimyrsa (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Orbactiv (Melinta), another IV formulation of oritavancin, was approved in 2014 for the same indication. Kimyrsa has a smaller infusion volume (250 mL vs 1 L) and a shorter infusion time (1 hour vs 3 hours) compared to Orbactiv (see Table 1).
Issue 1543 · March 26, 2018
Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections (online only)

View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections

Med Lett Drugs Ther. 2018 Mar 26; 60(1543):e59-62
View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections
Issue 1532 · October 23, 2017
Drugs for Common Bacterial Infections in Adults

Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):171-7
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Issue 1459 · January 5, 2015
Oritavancin (Orbactiv) for Skin and Skin Structure Infections

The FDA has approved oritavancin ( Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin…

Med Lett Drugs Ther. 2015 Jan 5; 57(1459):3-5
The FDA has approved oritavancin ( Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria in adults. It is the third lipoglycopeptide antibiotic to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.
Issue 1449 · August 18, 2014
Two New Drugs for Skin and Skin Structure Infections

The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin ( Dalvance – Durata) is a…

Med Lett Drugs Ther. 2014 Aug 18; 56(1449):73-5
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin ( Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ) . Tedizolid phosphate ( Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox) . A third IV antibiotic, oritavancin (Orbactiv) , recently approved by the FDA for the same indication, will be reviewed in a future issue.